Insider Selling: Questcor Pharmaceuticals CEO Sells 40,000 Shares of Stock (QCOR)
Questcor Pharmaceuticals (NASDAQ:QCOR) CEO Don M. Bailey sold 40,000 shares of Questcor Pharmaceuticals stock on the open market in a transaction that occurred on Friday, June 13th. The stock was sold at an average price of $89.83, for a total value of $3,593,200.00. The sale was disclosed in a document filed with the SEC, which is available at this link.
Shares of Questcor Pharmaceuticals (NASDAQ:QCOR) traded up 2.86% during mid-day trading on Tuesday, hitting $91.11. The stock had a trading volume of 1,399,914 shares. Questcor Pharmaceuticals has a one year low of $42.01 and a one year high of $94.20. The stock has a 50-day moving average of $88.28 and a 200-day moving average of $70.60. The company has a market cap of $5.388 billion and a P/E ratio of 16.73.
Questcor Pharmaceuticals (NASDAQ:QCOR) last announced its earnings results on Monday, April 28th. The company reported $1.40 earnings per share for the quarter, missing the analysts’ consensus estimate of $1.61 by $0.21. The company had revenue of $227.10 million for the quarter, compared to the consensus estimate of $239.81 million. During the same quarter last year, the company posted $0.76 earnings per share. Questcor Pharmaceuticals’s revenue was up 68.1% compared to the same quarter last year. Analysts expect that Questcor Pharmaceuticals will post $6.89 EPS for the current fiscal year.
A number of analysts have recently weighed in on QCOR shares. Analysts at Mizuho downgraded shares of Questcor Pharmaceuticals from a “buy” rating to a “neutral” rating in a research note on Monday, May 19th. They now have a $92.00 price target on the stock. Separately, analysts at Piper Jaffray downgraded shares of Questcor Pharmaceuticals from an “overweight” rating to a “neutral” rating in a research note on Monday, May 12th. They now have a $98.00 price target on the stock, up previously from $96.00. Finally, analysts at Oppenheimer reiterated an “outperform” rating on shares of Questcor Pharmaceuticals in a research note on Monday, April 21st. They now have a $86.00 price target on the stock, down previously from $99.00. Six analysts have rated the stock with a hold rating and five have given a buy rating to the stock. The company has an average rating of “Hold” and an average target price of $84.20.
Questcor Pharmaceuticals, Inc (NASDAQ:QCOR) is a biopharmaceutical company.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.